[Treatment of hematological malignancies with recombinant leukocyte A interferon (rIFN-alpha A)]. 1984

R Ohno, and Y Kodera, and M Ogura, and T Murase, and N Emi, and M Okumura, and Y Morishita, and E Nagura, and S Minami, and Y Morishima

Twenty-three cases of hematological malignancies (18 plasma cell neoplasm, 2 leukemia and 2 malignant lymphoma) were treated with recombinant human leukocyte interferon (rIFN-alpha A). Among plasma cell neoplasms, excellent and good responses were obtained in 1 case of IgG myeloma and 1 case of Bence-Jones myeloma respectively and fair response was obtained in 5 other cases. Response rats was 11.4%, or 38.9% if fair response was included. Partial remission was obtained in 1 case of chronic lymphocytic leukemia. In one of 2 cases of acute lymphoblastic leukemia, marked reduction of peripheral leukemia cells was noted. Side effects included fever (65%), malaise (20%), nausea-anorexia (43%), leukopenia (52%) and thrombocytopenia (52%). However, all were not serious and disappeared quickly after discontinuation of rIFN-alpha A.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007945 Leukemia, Lymphoid Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts. Leukemia, Lymphocytic,Lymphocytic Leukemia,Lymphoid Leukemia,Leukemias, Lymphocytic,Leukemias, Lymphoid,Lymphocytic Leukemias,Lymphoid Leukemias
D008223 Lymphoma A general term for various neoplastic diseases of the lymphoid tissue. Germinoblastoma,Lymphoma, Malignant,Reticulolymphosarcoma,Sarcoma, Germinoblastic,Germinoblastic Sarcoma,Germinoblastic Sarcomas,Germinoblastomas,Lymphomas,Lymphomas, Malignant,Malignant Lymphoma,Malignant Lymphomas,Reticulolymphosarcomas,Sarcomas, Germinoblastic
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

R Ohno, and Y Kodera, and M Ogura, and T Murase, and N Emi, and M Okumura, and Y Morishita, and E Nagura, and S Minami, and Y Morishima
February 1984, Clinical immunology and immunopathology,
R Ohno, and Y Kodera, and M Ogura, and T Murase, and N Emi, and M Okumura, and Y Morishita, and E Nagura, and S Minami, and Y Morishima
December 1984, Cancer,
R Ohno, and Y Kodera, and M Ogura, and T Murase, and N Emi, and M Okumura, and Y Morishita, and E Nagura, and S Minami, and Y Morishima
January 1986, Archives of dermatological research,
R Ohno, and Y Kodera, and M Ogura, and T Murase, and N Emi, and M Okumura, and Y Morishita, and E Nagura, and S Minami, and Y Morishima
April 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
R Ohno, and Y Kodera, and M Ogura, and T Murase, and N Emi, and M Okumura, and Y Morishita, and E Nagura, and S Minami, and Y Morishima
December 1991, Current opinion in biotechnology,
R Ohno, and Y Kodera, and M Ogura, and T Murase, and N Emi, and M Okumura, and Y Morishita, and E Nagura, and S Minami, and Y Morishima
February 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
R Ohno, and Y Kodera, and M Ogura, and T Murase, and N Emi, and M Okumura, and Y Morishita, and E Nagura, and S Minami, and Y Morishima
April 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
R Ohno, and Y Kodera, and M Ogura, and T Murase, and N Emi, and M Okumura, and Y Morishita, and E Nagura, and S Minami, and Y Morishima
June 1985, British journal of cancer,
R Ohno, and Y Kodera, and M Ogura, and T Murase, and N Emi, and M Okumura, and Y Morishita, and E Nagura, and S Minami, and Y Morishima
January 1986, Cancer immunology, immunotherapy : CII,
R Ohno, and Y Kodera, and M Ogura, and T Murase, and N Emi, and M Okumura, and Y Morishita, and E Nagura, and S Minami, and Y Morishima
January 1997, Haematologica,
Copied contents to your clipboard!